The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering by Eli Lilly and Company of $6.5 billion aggregate principal amount of senior notes, consisting of $1 billion of its 4.550% notes due 2028, $1.25 billion of its 4.750% notes due 2030, $1 billion of its 4.900% notes due 2032, $1.25 billion of its 5.100% notes due 2035, $1.25 billion of its 5.500% notes due 2055 and $750 million of its 5.600% notes due 2065.

Eli Lilly and Company is a worldwide research-based pharmaceutical company. The company has been pioneering life-changing discoveries for nearly 150 years, and today its medicines help tens of millions of people across the globe. Eli Lilly manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its products are sold in approximately 105 countries.

The Davis Polk capital markets team included partner Yasin Keshvargar and associate Michael Schuster. The tax team included counsel Yixuan Long and associates Jeff Metzger and David J. Beer. The environmental team included counsel Loyti Cheng and associate Timothy J. Sullivan. The intellectual property team included partner David R. Bauer and associate Joshua Shirley. All members of the Davis Polk team are based in the New York office.

Copy link to share post